candesartan has been researched along with Lung Adenocarcinoma in 1 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ji, Q | 1 |
| Shi, S | 1 |
| Ma, B | 1 |
| Zhang, W | 1 |
| An, H | 1 |
| Guo, S | 1 |
1 other study available for candesartan and Lung Adenocarcinoma
| Article | Year |
|---|---|
Drug repurposing and molecular mechanisms of the antihypertensive drug candesartan as a TMEM16A channel inhibitor.
Topics: Adenocarcinoma of Lung; Antihypertensive Agents; Calcium; Chloride Channels; Drug Repositioning; Hum | 2023 |